RxDoctor Payments Data

Maureen Watts, MD

Neurology · Dallas, TXNPI 1750497434

Payments from drug & device makers

$47,907in general payments, 2019–2025

Across 424 payments — averaging $112.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$43K
  • Lilly USA, LLC$815
  • Teva Pharmaceuticals USA, Inc.$518
  • Amgen$448
  • Lundbeck LLC$417
  • Supernus Pharmaceuticals, Inc.$339
  • plus $2K from 22 others

What the payments were for

  • Speaking & faculty fees$39,63383%
  • Travel & lodging$1,6743%
  • Food & beverage$6,60114%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,907 in reported general payments places this provider in the 80th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$26,864
Medicare patients
148
Services billed
224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate26$47,006
Aimovig AutoinjectorErenumab-Aooe51$43,785
Emgality PenGalcanezumab-Gnlm27$18,823
UbrelvyUbrogepant11$14,801
QuliptaAtogepant14$14,736
Emgality SyringeGalcanezumab-Gnlm16$11,202
Sumatriptan Succinate53$3,703
RizatriptanRizatriptan Benzoate37$892
Tizanidine Hcl41$436
Zonisamide15$372
Topiramate27$236
Gabapentin14$214
Eletriptan HbrEletriptan Hydrobromide14$193
Baclofen13$187
Clonazepam20$129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$246$47,00626 claims
AbbVieUbrelvy, Qulipta$43,397$29,53725 claims
Upsher-smith Laboratories LLCTopiramate$313$23627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,246 neurology providers in Texas.

Other neurology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →